Compare · CLSD vs NVO
CLSD vs NVO
Side-by-side comparison of Clearside Biomedical Inc. (CLSD) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLSD and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 1710.0x CLSD ($112.2M).
- Over the past year, CLSD is down 96.3% and NVO is down 44.9% - NVO leads by 51.4 points.
- NVO has hit the wire 8 times in the past 4 weeks while CLSD has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 8 for CLSD).
- Company
- Clearside Biomedical Inc.
- Novo Nordisk A/S
- Price
- $0.43-27.67%
- $41.58-3.18%
- Market cap
- $112.2M
- $191.82B
- 1M return
- -88.68%
- -9.16%
- 1Y return
- -96.28%
- -44.88%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2016
- News (4w)
- 0
- 8
- Recent ratings
- 8
- 25
Clearside Biomedical Inc.
Clearside Biomedical, Inc., a biopharmaceutical company, engages in the developing and delivering treatments that restore and preserve vision for people with serious eye diseases. Its product includes CLS-AX, an axitinib for suprachoroidal injection which is in Phase 1/2a clinical trial. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CLSD
- SEC Form S-8 POS filed by Clearside Biomedical Inc.
- SEC Form S-8 POS filed by Clearside Biomedical Inc.
- SEC Form S-8 POS filed by Clearside Biomedical Inc.
- SEC Form S-8 POS filed by Clearside Biomedical Inc.
- SEC Form S-8 POS filed by Clearside Biomedical Inc.
- SEC Form S-8 POS filed by Clearside Biomedical Inc.
- SEC Form S-8 POS filed by Clearside Biomedical Inc.
- SEC Form S-8 POS filed by Clearside Biomedical Inc.
- SEC Form POS AM filed by Clearside Biomedical Inc.
- SEC Form S-8 POS filed by Clearside Biomedical Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care